SCHEMBL714081

SCHEMBL714081

Cc1n[nH]c(Nc2ccc(S(=O)(=O)Nc3nccs3)cc2)c1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
POLB P06746 2/20 0.56
ILK Q13418 1/20 0.52
SCN9A Q15858 3/20 0.52
SCN1A P35498 2/20 0.52
SCN5A Q14524 2/20 0.52
SCN8A Q9UQD0 2/20 0.52
SCN3A Q9NY46 2/20 0.52
SCN4A P35499 1/20 0.52
SCN2A Q99250 1/20 0.52
SCN10A Q9Y5Y9 1/20 0.52
SCN1B Q07699 1/20 0.52
PKM P14618 3/20 0.49
ALDH1A1 P00352 2/20 0.49
EGFR P00533 1/20 0.49
KDR P35968 1/20 0.49
CYP3A4 P08684 1/20 0.49
PTGS1 P23219 1/20 0.49
PPIA P62937 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713861 0.80 MEN1 (0.56) MEN1KMT2APOLBSCN9ASCN1A
SCHEMBL686515 0.78 ILK (0.76) ILKALDH1A1EGFRKDRKDM4E
SCHEMBL713283 0.77 KMT2A (0.52) MEN1KMT2APOLBSCN9ASCN1A
SCHEMBL714065 0.74 MEN1 (0.64) MEN1KMT2APOLBSCN9ASCN1A
SCHEMBL712071 0.74 MEN1 (0.58) MEN1KMT2APOLBSCN1ASCN5A
SCHEMBL712318 0.74 MEN1 (0.63) MEN1KMT2APOLBSCN9ASCN1A
SCHEMBL326633 0.73 ALDH1A1 (0.71) MEN1KMT2ASCN9ASCN1ASCN5A
SCHEMBL713988 0.73 ALDH1A1 (0.64) MEN1KMT2APOLBSCN9ASCN1A
SCHEMBL713877 0.73 POLB (0.74) MEN1KMT2APOLBSCN9ASCN1A
Hydrochloric Acid SCHEMBL27575105 0.72 ALDH1A1 (0.69) MEN1KMT2ASCN9ASCN1ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A MEN1 4426/4885KMT2A 1945/4885POLB 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.